Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.98 |
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.98 |
| ▸ | SLC10A1 | Q14973 | 3/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.84 |
| ▸ | RAB9A | P51151 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | BLM | P54132 | 1/20 | 0.84 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.80 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.80 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | CA1 | P00915 | 2/20 | 0.70 |
| ▸ | CA2 | P00918 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.69 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taurocholic Acid SCHEMBL9224412 | 1.00 | GPBAR1 (0.98) | GPBAR1SLC10A2SLC10A1TSHRRAB9A | |
| Taurocholic Acid SCHEMBL9900941 | 0.99 | GPBAR1 (0.97) | GPBAR1SLC10A2SLC10A1TSHRRAB9A | |
| Taurocholic Acid SCHEMBL9900942 | 0.99 | GPBAR1 (0.97) | GPBAR1SLC10A2SLC10A1TSHRRAB9A | |
| Taurocholic Acid SCHEMBL3706 | 0.99 | GPBAR1 (1.00) | GPBAR1SLC10A2SLC10A1TSHRRAB9A | |
| Taurocholic Acid SCHEMBL22852508 | 0.99 | GPBAR1 (1.00) | GPBAR1SLC10A2SLC10A1TSHRRAB9A | |
| Taurocholic Acid SCHEMBL24486612 | 0.99 | GPBAR1 (1.00) | GPBAR1SLC10A2SLC10A1TSHRRAB9A | |
| Taurocholic Acid SCHEMBL10696857 | 0.99 | GPBAR1 (1.00) | GPBAR1SLC10A2SLC10A1TSHRRAB9A | |
| Taurocholic Acid SCHEMBL20493965 | 0.99 | GPBAR1 (1.00) | GPBAR1SLC10A2SLC10A1TSHRRAB9A | |
| Taurocholic Acid SCHEMBL24001492 | 0.99 | GPBAR1 (1.00) | GPBAR1SLC10A2SLC10A1TSHRRAB9A | |
| Taurocholic Acid SCHEMBL435030 | 0.99 | GPBAR1 (1.00) | GPBAR1SLC10A2SLC10A1TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058454-A1 | BIOLOGICAL DELIVERY SYSTEMS | PARTICELLA INC (US) | 2024-02-22 | — | — | US | claimed |
| EP-4259099-A1 | BIOLOGICAL DELIVERY SYSTEMS | Particella, Inc. (US) | 2023-10-18 | — | — | EP | claimed |
| WO-2022132678-A1 | BIOLOGICAL DELIVERY SYSTEMS | DNALITE THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| CN-114469826-A | Gel type Zhejiang radix ophiopogonis whitening mask and preparation method thereof | 浙江省林业科学研究院 | 2022-05-13 | — | — | CN | claimed |
| CN-114195852-A | Preparation method of 3 beta, 7 beta-dihydroxy-5 beta-cholanic acid | 中山百灵生物技术股份有限公司 | 2022-03-18 | — | — | CN | claimed |
| WO-2021070883-A1 | HUMAN NTCP-BINDING ANTIBODY CAPABLE OF INHIBITING INFECTION OF HEPATITIS B VIRUS (HBV) TO HUMAN HEPATOCYTES | 国立研究開発法人理化学研究所 | 2021-04-15 | — | — | WO | claimed |
| CN-112505187-A | Method for detecting bile acid in excrement by UPLC-MS/MS (ultra Performance liquid chromatography-Mass Spectrometry/Mass Spectrometry) combination | 北京诺禾致源科技股份有限公司 | 2021-03-16 | — | — | CN | claimed |
| US-20210071097-A1 | Droplet for Fuels | KAMTERTER PRODUCTS, LLC (US) | 2021-03-11 | — | — | US | claimed |
| WO-2020182228-A1 | METHOD OF REFINING SODIUM TAUROCHOLATE | 美药星（南京）制药有限公司 | 2020-09-17 | — | — | WO | claimed |
| EP-3443335-A1 | SYSTEMS AND METHODS FOR ELECTROCHEMICAL TRIGLYCERIDES ASSAYS | Polymer Technology Systems, Inc. (US) | 2019-02-20 | — | — | EP | claimed |
| US-20080063708-A1 | Pharmaceutical Compositions of Amorphous Dispersions of Drugs and Lipophilic Microphase-Forming Materials | LONZA BEND INC. | 2008-03-13 | — | — | US | claimed |
| CN-100349915-C | Amido glycoside of sea pearl oyster, prepartion method, and usage | NANHAI INST OF OCEAN C A S (CN) | 2007-11-21 | — | — | CN | claimed |
| CN-1916021-A | Amido glycoside of sea pearl oyster, prepartion method, and usage | NANHAI INST OF OCEAN C A S (CN) | 2007-02-21 | — | — | CN | claimed |
| CN-1810947-A | Garlic oil refining process and the prepn process of its emulsion and solid nanometer liposome particle | GUO TAO (CN) | 2006-08-02 | — | — | CN | claimed |
| EP-1653927-A2 | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AMORPHOUS DRUGS AND LIPOPHILIC MICROPHASE-FORMING MATERIALS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| CN-1593649-A | Method for preparing insulin oral formulation | YU XIAOLING (CN) | 2005-03-16 | — | — | CN | claimed |
| US-20050031693-A1 | Combination of a solid adsorbate and a lipophilic microphase-forming material results in improved dissolved concentration of the drug in the aqueous use environment | PFIZER INC | 2005-02-10 | — | — | US | claimed |
| WO-2005011635-A2 | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AMORPHOUS DRUGS AND LIPOPHILIC MICROPHASE-FORMING MATERIALS | PFIZER PRODUCTS INC. (US) | 2005-02-10 | — | — | WO | claimed |
| CN-1259142-A | Zinc-free insulin crystal composition for lung | NOVO NORDISK AS (DK) | 2000-07-05 | — | — | CN | claimed |
| CN-1171049-A | Powder formulations containing melezitose as diluent | ASTRA AB (SE) | 1998-01-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080063708-A1 | Pharmaceutical Compositions of Amorphous Dispersions of Drugs and Lipophilic Microphase-Forming Materials | ABCG2, LIPA, ABCB1 | GPBAR1 1234/4885SLC10A2 444/4885SLC10A1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.